R&D expense · 2018–2025

Castle Biosciences R&D expense

$51.9M−0.4% · FY2025

Castle Biosciences (CSTL) reported $51.9M in R&D expense for fiscal 2025, −0.4% year on year.

$4.9M2018$7.4M2019$13.3M2020$29.6M2021$44.9M2022$53.6M2023$52.0M2024$51.9M2025
Castle Biosciences — R&D expense, 2018–2025
Fiscal yearR&D expenseChangeFiling
FY20252025-12-31$51.9M−0.4%Open →
FY20242024-12-31$52.0M−2.9%Open →
FY20232023-12-31$53.6M+19.4%Open →
FY20222022-12-31$44.9M+51.5%Open →
FY20212021-12-31$29.6M+123.6%Open →
FY20202020-12-31$13.3M+79.5%Open →
FY20192019-12-31$7.4M+52.1%Open →
FY20182018-12-31$4.9M—Open →

R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2018–2025 compound annual growth +40.3%

R&D expense at companies of similar size

Full ranking by R&D expense →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Castle Biosciences R&D expense |url=https://companiesranked.com/en/company/castle-biosciences/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Castle Biosciences R&D expense. CompaniesRanked. https://companiesranked.com/en/company/castle-biosciences/research-and-development-expense

BibTeX

@misc{companiesranked-en-company-castle-biosciences-research-and-development-expense-2026,
  author       = {{CompaniesRanked}},
  title        = {{Castle Biosciences R\&D expense}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/castle-biosciences/research-and-development-expense}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-K · 0001628280-26-012272 · February 26, 2026

{{cite web |title=Castle Biosciences R&D expense — 10-K (0001628280-26-012272) |url=https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Castle Biosciences overview